Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 [Urologic Oncology]

Conclusion
Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Smith, De Bono, Sternberg, Le Moulec, Oudard, De Giorgi, Krainer, Bergman, Hoelzer, De Wit, Bogemann, Saad, Cruciani, Thiery-Vuillemin, Feyerabend, Miller, Houede, Hussain, Lam, Polikoff, Stenzl, Mainwaring, Ramies, Hessel, Weitzman, Fizazi Tags: Systemic Therapy Urologic Oncology Source Type: research